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Abstract
The identification of new markers, the expression of which defines new phenotipically and functionally distinct cell subsets,
is a main objective in cell biology. We have addressed the issue of identifying new cell specific markers with a reverse
proteomic approach whereby approximately 1700 human open reading frames encoding proteins predicted to be
transmembrane or secreted have been selected in silico for being poorly known, cloned and expressed in bacteria. These
proteins have been purified and used to immunize mice with the aim of obtaining polyclonal antisera mostly specific for
linear epitopes. Such a library, made of about 1600 different polyclonal antisera, has been obtained and screened by flow
cytometry on cord blood derived CD34+CD45dim cells and on peripheral blood derived mature lymphocytes (PBLs). We
identified three new proteins expressed by fractions of CD34+CD45dim cells and eight new proteins expressed by fractions
of PBLs. Remarkably, we identified proteins the presence of which had not been demonstrated previously by transcriptomic
analysis. From the functional point of view, looking at new proteins expressed on CD34+CD45dim cells, we identified one
cell surface protein (MOSC-1) the expression of which on a minority of CD34+ progenitors marks those CD34+CD45dim cells
that will go toward monocyte/granulocyte differentiation. In conclusion, we show a new way of looking at the
membranome by assessing expression of generally neglected proteins with a library of polyclonal antisera, and in so doing
we have identified new potential subsets of hematopoietic progenitors and of mature PBLs.
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Introduction
The identification of phenotypically distinct cell subsets within
apparently homogeneous cell populations is a key step toward the
identification and functional characterization of new cell subsets
having both specific effector functions and differentiation path-
ways. Immunological studies offer one of the best examples of this
assumption. From the discovery of the main T lymphocyte subsets
in the 1970s [1] to the recent identification of the poorly
represented regulatory subsets such as Treg and Th17 [2,3,4,5],
every time that a new T cell subset has been characterized
phenotypically, a significant improvement in the understandings of
the effector functions of the immune system has been subsequently
achieved.
All the human genome has been sequenced and annotated
[6,7,8,9], and a significant amount of gene products have been
studied in some details. However, the distribution and function of
a large fraction of human gene products is still unknown
[6,10,11,12]. Generally, in the present post-genomic era, the
identification of new proteins on cells of interest has resulted either
from classical proteomics approaches [13,14,15] or from gene
expression profile analyses [16,17]. Both these approaches are
sensitive enough to identify new genes and proteins expressed in a
given cell population [18,19,20,21]. However, it is impossible to
assess whether differences in the expression levels of proteins occur
in all of the cells analyzed or in a subset of them. It is therefore
difficult to study those cell subsets or lineages that are poorly
represented within a population and the amount of starting
material may remarkably affect the results obtained with these
methods [22].
One of the most effective ways to identify and characterize new
proteins is the use of specific antibodies. We therefore developed
an experimental approach aimed at obtaining a polyclonal
antibody library composed of individual antisera specific for most
of those thousands of poorly characterized human proteins located
outside the cell. We focused our attention on proteins that are
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predicted in silico to be secreted [23] or transmembrane, and to
have at least one domain predicted to be ‘‘outside’’ the cell. These
proteins are therefore likely to be used by cells to interact with the
external milieu. We assumed that it would have been possible to
characterize unknown gene products as new subset-defining
proteins with specific antibodies.
We previously selected in silico 5086 ORFs potentially encoding
for membrane or secreted proteins so far poorly characterized in
distribution and function. These genes have been cloned and
expressed in Escherichia coli. The recombinant proteins have been
purified and used to immunize groups of five mice generating a
library of 1559 polyclonal antisera (Data S1, [24])
In this work we describe the use of this library to assess the
expression of poorly characterized membrane bound proteins on
immature or mature hematopoietic cells from healthy donors by
flow cytometry. These analyses were performed on cord-blood
derived CD34+CD45dim cells or on Peripheral Blood Lympho-
cytes (PBLs) and resulted in the identification of eight new proteins
expressed by PBLs subset and of three new proteins expressed on
subsets of CD34+CD45dim cells.
We show that this high throughput screening is suitable for the
study of very poorly represented cell populations, such as CD34+
cell subsets within the whole cord blood cell population. Moreover,
the use of flow cytometry allows not only to estimate the
percentage of cells expressing a given cell surface protein but also
to separate live positive cells for further studying phenotypical and
functional features of the newly identified population.
Methods
Preparation of a library of polyclonal antisera specific for
human unknown proteins
Details on the library of antisera used in the present work are
presented in full in Data S1. Briefly the genes coding for proteins
predicted to be transmembrane or secreted with unknown
distribution and functions were selected and expressed in E. coli.
The recombinant proteins were then purified by Ion Metal
Affinity Chromatography (IMAC) and used to immunize groups of
five mice to produce polyclonal antisera.
Cell Preparation and Purification
Peripheral blood and cord blood were obtained from healthy
donors after the signature of specific informed consent, fulfilling
the requirement of the ethical committee of the Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico. The
mononuclear cells from healthy donors blood and cord blood
were obtained by density gradient centrifugation on Lympholyte-
H (Cedarlane Laboratories Ltd) and immediately analyzed after
the separation. PBL activation was induced on overnight by the
addition on medium phytohemagglutinin (PHA) 1 mg/ml
(ROCHE Diagnostic GmbH) and IL-2 100 U/ml (Novartis).
The cells were cultured at 37uC and 5% CO2 in RPMI
supplemented with 10%FBS (EuroClone S.p.A) and antibiotics
(GIBCO)
Flow Cytometry
Flow cytometry screening of the library was performed on 2 to
56105 PBL or 56106 cord blood mononuclear cells. Resting or
activated PBMCs were stained in a three-step procedure. Cells
were incubated for 20 min at room temperature with 50% NHS
(Euroclone) in PBS (Euroclone) to block Fc receptor; then
incubated with anti-serum at the optimal concentration (1:50 to
1:450 dilution) in 5%NHS-PBS (Facs wash) for 10 min at 4uC,
washing two time at 1500 rpm for 3 min and finally incubated
with Goat anti mouse RPE (SouthernBiotech) at 1:200 dilution for
10 min at 4uC, washing two time with Facs wash at 1500 rpm for
3 min.
Multi color FACS analysis on cord blood cells was performed as
following. Cells were stained for the first three steps as PBL then
incubated with mouse IgG (SIGMA) at 4 mg/106 cells for 1 hour
at 4uC then the following mAbs were added: CD34, (IOT
Coulter), CD45 (ImmunoTools), or for PBL in multi color CD3,
CD19, CD56, CD71, Glycophorin A, CD7, CD33, CD38, CD10
(BD Biosciences), CD117 (IOT Coulter), CD133/2 (Macs
Miltenyi Biotec GmbH), Mouse isotype-matched was used as
negative controls. The samples were acquired using a FACScanto
II analyzer (Becton Dickinson) and data were processed with the
program FlowJo (Flow Cytometry Analysis Software).
Amplification by RT PCR of the transcripts corresponding
to the newly identified proteins
RNA extraction was performed using RNeasy Mini Kit or
RNeasy Micro Kit (QIAGEN) on peripheral blood, cord blood
cells or magnetically purified CD34 positive cells using CD34
Miltenyi microbeads kit. Cells were then lysates and homogenized
with QIAshredder homogenizer (QIAGEN).
cDNA synthesis was performed using SuperScript III First-
Strand Synthesis SuperMix (Invitrogen).
RT-PCR primers 59-39 sequences:
TMCC1 379 fw CAGGAGGAGCGATATAGATGTG
379 rev TGGCTACAGTGGAGACAAAG
MOSC-1 194 fw TTCCTGAAGTCACAGCCCTAC
194 rev GCATCTGGAACAAGCCATCAC
SUSD3 452 fw A TTGTGAGCTGTGCCATCATCC
452 rev A TGTGGTGAAGCTGTGGTTGTC
TMEM126 314 fw GGCGACATTTGGAACAAC
314 rev TTTGGTGGCAGTGGAACG
LPPR2 1174 fw AGCGATGTACGTGACTCTC
1174 rev CAGTTCTGCGACTTGGATG
GSG1-L 444 fw b TCTGTCACCACGCTCAACTCC
444 rev b AAGACCCAGCACTGTCGGTTC
TMEM38 147 fw CACCCAGCATCTGGCAATATC
147 rev GCAACATCTACCGGCTTTGAG
KRTCAP3 665 fw AGGACTGCTGGATCCTCTG
665 rev GCACCTGCTGTCCTAAACC
CRISP-1 26nested2 fw TAAGCTCGTCACCGACTTG
26nested2 fw CTCCTCATCGTCACAGCATAG
26a fw ACACAACGCCCTCAGGAGAAG
26a rev TGGCGGCAAGATGCAATGG
26b fw GTTTGGGCCACATCTTAC
26b rev CGTCACAGCATAGAACAG
Clonogenic Assay
Clonogenic assays were performed using aserum positive cells,
isolated using FACSAria cell sorter (Becton Dikinson). The cells
were plated at 250 cells/plate in METHOCULT H4433 complete
methylcellulose medium (StemCell Technologies). Cultures were
incubated for 14 days in incubator adjusted to 37uC, 5%CO2 and
.95% humidity.
Transient Transfection
To carry out transient transfection experiments, we used
MicroPorator MP-100, a pipette-type electroporation system
(NanoEnTek Inc). The cells were dissociated by a brief treatment
with trypsin-EDTA (Euroclone). The indicated plasmid DNAs
were introduced into 56105 dissociated cells in 10 ml volumes
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according to manufacturer’s instructions (3 pulses with 10 msec
duration at 1600 voltage; Digital Bio Technology).
Electroporated cells were then seeded into 6-well culture dishes
(Nunc) containing 2 ml of culture media. After 24–48 hrs cells
were harvested and lysated for Western blot analysis
Western blot analysis
Whole-cell extracts were loaded on pre-casted sodium dodecyl
sulfate (SDS)-polyacrylamide gels (Bio-Rad Laboratories S.r.l.) and
transferred to Hybond-P PVDF membranes (GE Healthcare)
using Towbin’s buffer (25 mM Tris, pH 8.3, 192 mM glycine and
20% methanol). The blots were blocked in PBS containing 0.5%
Tween 20 (SIGMA) and 5% not fat milk and incubated with
primary antibody (anti-myc mAb 9E10 clone or antiserum) at
room temperature for 1 hr. The blots were then washed four times
with PBS/0.5% Tween-20. Primary antibody binding was
subsequently detected by incubation for 1 hour with secondary
antibodies goat anti mouse HRP (SouthernBiotech). The blots
were then developed using the SuperSignal West Dura Extended
Duration Substrate (Thermo Fisher Scientific).
Results
Preparation and validation of a library of polyclonal
antisera specific for human unknown proteins
We identified in the human genome 7902 genes coding for
proteins that are predicted to be either transmembrane or secreted.
For about two-thirds of them there is a little information on
distribution and function. In order to gain insight into the function
of these neglected proteins we generated a specific antibody library
against proteins poorly characterized predicted as integral mem-
brane or secreted. We have selected about 3000 genes, cloned and
expressed them in E. coli, purified the recombinant proteins and
immunized groups of five mice with each individual protein
(Figure 1). We thus obtained a library of 1559 mouse antisera
specific for 1287 poorly known human secreted or transmembrane
proteins (for 214 genes more than one protein fragment were
selected) (Griffantini, Pagani et al., Data S1).
As our mice antisera were raised against human proteins
expressed in bacteria, most likely they are directed against linear
epitopes, so a key question was whether such antibodies would
recognize the corresponding proteins on the surface of human cells.
To obtain proof of concept that our antibody library had the
potential to identify new cell surface proteins, we produced in
bacteria, with the same technology described above, antisera
specific for twenty well characterized proteins (i.e., with assigned CD
numbers) known to be present on hematopoietic cells and for which
very good monoclonal antibodies exist (Table 1). We then asked
whether we would be able to ‘‘identify’’ these proteins on living cells
by flow cytometry or on fixed and embedded tissues by immuno-
hystochemistry (IHC). Table 1 summarizes the whole results and
shows that by flow cytometry we could ‘‘identify’’ 12/20 (60%) well-
characterized proteins on the surface of living PBLs. Remarkably,
with IHC on fixed and embedded lymph node tissues we
‘‘identified’’ 11/14 (85%) known proteins in lymphoid cells.
Figure 2 shows representative stainings of lymphocytes with
these antisera by flow cytometry. PBLs were stained with our
polyclonal anti-CD8 antiserum in comparison with a commercial
anti-CD8 monoclonal antibody (mAb) used alone or in a
combination with commercial anti-CD3 and anti-CD4 mAbs
(Panel A). Other examples of staining with antisera from the
library are shown in Panel B. PBMCs from healthy donors were
stained with anti CD2, CD1d, CD8 alpha, CD25, CD72, CD80,
CD38, CD86. The expression of CD25 was assessed upon a
24 hours activation of PBMCs with 1 mg/ml of PHA. The
expression of CD80 and CD86 was assessed upon gating on
monocytes after a 24 hours activation of PBLs with 1 mg/ml of
PHA. The expression of CD133 was analyzed on cord blood
derived CD34+, CD45dim cells. In all the cases serum from not
immunized mice was used as negative control. For all the proteins
analyzed the staining was consistent with the expected percentage
of positive cells. The antisera specific for well-known proteins were
tested also on inflamed lymph-nodes tissues by IHC. The
representative IHC experiments on lymph nodes are shown in
Figure S1.
From the above results we concluded that our approach would
be suitable to identify new molecules on a cell population of choice
by IHC or flow cytometry, and most importantly, that antisera
from the library can be used in multi-parametric analysis by flow
cytometry. Although the use of IHC would result in a lower
number of false negative antibodies compared to flow cytometry,
we decided to utilize flow cytometry to screen human hemato-
poietic cells, because of the possibility to gate and analyze very rare
cells subsets (,1–2%) which would pass mostly undetected in a
screening performed by IHC.
Identification of new proteins expressed on the surface
of PBLs and CD34+CD45dim cells
After validating the approach, we screened our antisera library
on resting or activated PBLs and cord blood samples with the aim
Figure 1. Schematic representation of the antisera library
generation.
doi:10.1371/journal.pone.0034395.g001
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at identifying molecules able to define new cell subsets within PBLs
and CD34+CD45dim cells. Each individual antiserum was tested
in three dilution points on at least three independent PBLs and at
least three independent cord blood samples. On PBLs, the
screening was performed on 56105 cells from either resting or
phytohemagglutinin (PHA)-stimulated lymphocytes. On cord
blood samples, 56106 cells were analyzed to eventually gate on
1000–2000 CD34+, CD45dim cells. In the search for new cell
subsets, we concentrated our efforts on antisera that were positive
for a fraction of the population we were interested in. Antisera that
resulted positive with these criteria after the first screening on
PBLs or CD34+ cells were validated on cell samples from ten
additional independent donors. Finally, to confirm the presence of
the transcript corresponding to the protein recognized by the
antiserum we assessed mRNAs by RT-PCR analysis on purified
cells.
Figure 3 shows that the high throughput screening of
hematopoietic cells with 1559 antisera led to the identification of
seven molecules expressed on PBL subsets (panel A), one new
molecule up-regulated on a subset of activated PBLs (Panel B) and
three new molecules expressed on a subset of CD34+CD45dim
cells (Panel C). To characterize the newly identified cell subsets, we
performed a multicolor FACS analysis of the antisera in
combination with monoclonal antibodies specific for the known
main subsets of PBLs (CD3+ T lymphocytes, CD19+ B
lymphocytes, or CD56+ Natural Killer cells) or CD34+ cells.
Figure 3A shows that four out of seven new molecules we
identified on PBLs (i.e., LPPR2, MOSC-1, TMEM38B and
GSG1L) are mainly present on B lymphocytes, whereas the other
three antisera specific for TMCC1, TMEM126B and SUSD3 are
Table 1. Comparison of the results obtained with antisera
specific for well-known proteins assessed both by FACS on
PBMCs from healthy donors and by IHC on inflamed lymph
nodes.
Symbol FACS IHC
CD1d positive nd
CD2 positive positive
CD3d negative negative
CD3e negative positive
CD8a positive positive
CD8b negative positive
CD27 positive positive
CD33 positive nd
CD38 positive nd
CD45 negative positive
CD72 positive nd
CD122 negative nd
CD161 negative nd
CD25, IL-2Ra positive positive
CD69 negative positive
CD71 negative positive
CD80 positive negative
CD86 positive positive
CD34 negative nd
CD133 positive nd
doi:10.1371/journal.pone.0034395.t001
Figure 2. FACS analysis with sera specific for well-known
proteins. (A) Comparison of the CD8 staining performed on PBL with
either a commercially available anti CD8 mAb (BD biosciences) or the anti
CD8 alpha antiserum at 1:100 dilution points. Both the samples were
stained also with commercially available anti CD3 and anti CD4 mAb (BD
biosciences). The distribution of CD4 and CD8 is analyzed upon gating on
CD3 positive cells. (B) Examples of staining with antisera from the library.
PBLs from healthy donors were stained with anti CD2, CD1d, CD8 alpha,
CD25, CD72, CD80, CD38, and CD86. The expression of CD25was assessed
upon a 24 hours activation of PBLs with 1 mg/ml of PHA. The expression
of CD80 and CD86 was assessed upon gating on monocytes after a
24 hours activation of PBLs with 1 mg/ml of PHA. The expression of CD133
was analyzed on cord blood derived CD34+, CD45dim cells. Serum from
not immunized mice was used as negative control in all the stainings.
doi:10.1371/journal.pone.0034395.g002
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positive on both T and B lymphocyte subsets. Figure S2 shows the
validation of this analysis on ten additional donors. The presence
of the transcripts was confirmed by RT-PCR performed either on
total peripheral blood mononuclear cells (PBMCs) (Figure 3D,
panel 1 and 2) or on CD34+CD45dim cells purified magnetically
with an anti-CD34 mAb out of cord blood cells (Figure 3D, panel
3).
Since the antisera of our library were raised in mice by using
proteins produced in bacteria, the possibility exists that they are
cross-reactive on human cells ex vivo. To rule out the possibility of
sera cross-reaction toward unrelated molecules, we cloned the
genes coding for the putatively identified proteins in a mammalian
expression vector in frame with a c-myc tag, transiently transfected
HeLa cells and assessed protein expression by western blot using
either the specific antiserum or an anti c-myc mAb. Figure 4 shows
that antisera recognized a band of the expected molecular weight,
whereas only two antisera (putatively specific for LPPR2 and
GSG1L) did not recognize a band of the expected molecular
weight indicating these two antisera could be cross-reactive,
originating false positive signals in the screening despite the
positive RT-PCR. These results were confirmed by FACS analysis
with the specific antisera on the same transfectants as shown in
Figure S3, indicating that a validation of the data coming from the
primary screening either by FACS or Western Blot is mandatory
to further exclude false positive signals.
From all the above experiments, we conclude that our reverse
proteomic approach to analyze the membranome is specific and
sensitive enough to allow the identification of new hematopoietic
cell subsets. Notably, we identified proteins the presence of which
had not been demonstrated previously by transcriptomic analysis.
For instance, we found (Fig. 3C) that a fraction of
CD34+CD45dim cells express MOSC-1 on their surface, whereas
previous gene expression profile analyses indicated a possible
expression of MOSC-1 on peripheral blood monocytes, myeloid
Figure 3. Results of sera screening by FACS on PBL and Cord Blood cells. (A) FACS analysis of sera positive on PBLs. PBLs were stained with
the indicated sera at the optimal dilution point (1:50 to 1:200). The samples were stained also with anti CD3, anti CD19 and anti CD56 mAbs to
analyze the sera reactivity upon gating on the different subpopulations. A plot representative of five different donors is shown for each serum. (B)
KRTCAP-3 specific serum recognizes PHA-treated cells. PBMCs are treated for 24 hours with 1 mg/ml of PHA. After the treatment both un-stimulated
and treated cells are stained with the KRTCAP-3-specific serum. (C) FACS analysis of sera positive on cord blood cells. Cord blood mononuclear cells
are stained with the indicated sera at the optimal concentration (1:50 to 1:100). The samples are stained also with anti CD45 and anti CD34 mAbs to
perform the analysis upon gating on CD34highCD45dim. A plot representative of a least 3 independent donors is shown. Il all the cases (A,B,C,) a
staining with the serum of not immunized mice was used as negative control. (D) RT-PCR analysis. a- cDNA from total PBMC were amplified with
primers specific for the indicated proteins. b- cDNA from both un-stimulated and PHA-treated PBMC was amplified with KRTCAP-3 specific primers.
KRTCAP3 expression is up regulated two to three times. Beta actin amplification is used as normalization. c- cDNA samples from CD34+CD45dim cells
were generated by retro-transcription of RNA extracted from a pool of CD34 positive cells from 2–3 independent cord blood units magnetically
purified using the Miltenyi CD34 microbeads kit according the manufacturer instruction. The purity of the CD34+CD45dim cells was usually .99%.
The samples were amplified with primers specific for the indicated proteins and described in the Methods section.
doi:10.1371/journal.pone.0034395.g003
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Figure 4. Assessment of antisera specificity on Hela transfected cells. Hela cells were transiently transfected with a myc-tag version of the
proteins identified with the sera library. At 24 hours from the transfection cells were lysated as described in the Method section. 40 mg of total
proteins were loaded on SDS page and a WB analysis was performed using both an anti myc mAb (9E10 clone) and the corresponding antiserum. (A)
WB analysis of Hela cells transfected with CRISP-1 and MOSC-1. In both the cases the anti myc mAb and the specific antiserum recognized a protein of
the expected molecular weight that is not present in the cells transfected with the mock vector. A comparable result was obtained wit KRTCAP-3 (B),
TMCC-1 (C), TMEM38B (D) and SUSD3 (E) transfected cells. The WB analysis of GSG1-L cells (E) and LPPR2 cells (F) shows that neither the anti myc nor
the specific antiserum is able to recognize in a specific way a protein in transfected cells.
doi:10.1371/journal.pone.0034395.g004
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hematopoietic precursors but not on more immature
CD34+CD45dim cells (http://symatlas.gnf.org/SymAtlas).
Identification of MOSC-1 as a marker of mono-
granulocyte development on CD34+CD45dim cells
To address functional aspects associated to the expression of
these new proteins, we focused our attention on MOSC-1, the
expression of which had not been reported previously on cord
blood derived CD34+CD45dim cells.
MOSC-1 (Moco Sulphurase domain containing protein-1) is a
potentially secreted protein that contains a MOSC domain. This
domain is predicted to be a sulfur-carrier domain that receives
sulfur abstracted by the pyridoxal phosphate-dependent NifS-like
enzymes, on its conserved cysteine, and delivers it for the
formation of diverse sulfur-metal clusters [25].
To assess whether the presence of MOSC-1 conferred peculiar
functions to the CD34+CD45dim cells, we separated CD34+ cells
expressing MOSC-1 (Figure 5A shows a representative plot) by
FACS and performed a colony forming cell (CFC) assay to
establish their differentiation capacity in comparison to the
MOSC-1 negative counterpart. Therefore, the FACS sorted cells
were plated in a semi-solid medium in the presence of a cocktail of
growth factors (SCF, Flt3L, IL-6, GM-CSF, IL-3 and EPO)
capable of sustaining proliferation and differentiation of different
hematological lineages. After 14 days of culture, erythroyd
progenitors would generate BFU (red) colonies, myelo-granulo-
cytes progenitors would generate CFU-GM, CFU-G, CFU-M
(white) colonies and the more immature cells would generate
CFU-GEMM (mixed) colonies.
Figure 5B shows that CD34+ cells expressing MOSC-1
generated almost exclusively white colonies, while the frequency
of mixed colonies is consistently reduced in comparison with
MOSC-1 negative and total CD34+CD45dim cells. Finally the
entire sample analyzed produced a negligible amount of red
colonies with a significant frequency difference toward total
CD34+CD45dim cells. These results suggest a commitment of
MOSC-1 positive cells toward myeloid lineage. Moreover, a
further phenotypic analysis performed on MOSC-1 positive
CD34+ cells (Figure 5C) showed CD133 and CD33 co-expression
together with no expression of CD7 and CD10, and a partial
expression of the myeloid marker CD13, thus suggesting possible
mono-granulocytic commitment. This possibility is consistent with
the reactivity of MOSC-1 antiserum on peripheral blood
monocytes (Figure 5D). Although Figure 5D shows a MOSC-1-
specific reactivity also toward B-lymphocytes, RT-PCR analysis
performed on purified PBMC subpopulations (Figure 5E) indicat-
ed that MOSC-1 transcript is present only in monocytes.
Moreover, differentiation assays on OP9 cells demonstrated that
CD34+ cells expressing MOSC-1 are not able to generate B cells
(Figure S4). Since MOSC-1 is potentially secreted, it is possible
that the protein produced and secreted by monocytes binds a
receptor on B cells. Further studies are necessary to understand the
reactivity of MOSC-1 positive serum on B cells, however the
results that we have obtained with MOSC-1 expressing
CD34+CD45dim cells are consistent with a monocyte commit-
ment of this cell subset.
We conclude that using this antibody library we could not only
identify new molecules expressed on subsets of cell populations of
interest, but could also demonstrate a correlation between a
phenotype and the functional commitment of the newly identified
cell subset.
Discussion
In this study we have described a library of mouse polyclonal
antisera specific for linear epitopes of poorly known human
proteins that were predicted to be either transmebrane or secreted.
We have shown that with this library it is possible to analyze the
cell surface of hematopoietic cells by flow cytometry and to
identify new subsets of both mature and hematopoietic cells. This
library is versatile—it can be used to screen any cell or tissue of
interest—and allows screening of a large (1287) repertoire of
‘‘neglected’’ human proteins for those that mark specifically new
subsets within apparently homogeneous cell populations.
The identification of new proteins on cells or tissues is generally
based either on transcriptomics, i.e., the assessment of mRNA
expression profile, or on proteomics, i.e., the direct identification
by mass spectrometry of proteins separated by 2D gels or liquid-
based separation methods. Transcriptomics allows analyzing and
compare large amount of samples at the same time [12], but poses
the problem of the correlation between mRNA and protein
expression levels. Proteomics is very informative but poses the
problem of the complexity of the approach that makes it not
suitable for high throughput screenings. In both cases, it is
impossible to assess whether differences in the expression levels of
genes or proteins occur in all of the cells analyzed or in a subset of
them. It is therefore difficult to study those cell subsets or lineages
that are poorly represented within a population. Our goal was to
study hematopoietic cell subsets by flow cytometry and we
therefore opted for an approach based on the direct identification
of proteins with an antibody library.
We elicited our antibody library using proteins expressed in
bacteria as immunogens. On one hand, antibodies raised against
human proteins expressed in bacteria and purified from inclusion
bodies are not ideal for the identification of human proteins
present on the cell membrane, as these quite often undergo
posttranslational modifications and structure conformations,
which are generally lost when the protein is expressed in bacteria.
Consequently, monoclonal antibodies specific for human proteins
expressed in bacteria have the limiting factor of the number of
antibodies that need to be screened to find the ones that recognize
the human proteins in their native form. We therefore utilized
polyclonal antisera that include a combination of specificities in
the same sample. On the other hand, the expression of human
antigens as his-tag proteins in bacteria has several practical
advantages such as the higher throughput-working pipeline, the
higher amount of proteins produced and the higher homogeneity
of the different batches.
Since these types of antibodies quite often recognize on the
native form of human proteins only primary sequence structure,
i.e., linear epitopes, and frequently they are even specific for
epitopes that are not present on the ‘‘real life’’ proteins, it was
important to obtain a proof of concept that our approach was
suited to identify proteins expressed on human cell membranes.
Therefore, we produced antisera specific for twenty well
characterized proteins known to be present on hematopoietic
cells and showed that we could identify 60% of known proteins on
the surface of living PBLs by flow cytometry and 85% of known
proteins in fixed and embedded lymphoid tissues by IHC. A likely
explanation for the superiority of IHC versus flow cytometry with
these antisera relies on the nature of the antigens used to
immunize mice. Indeed, human proteins on fixed and embedded
cells, rather than on living cells, are likely to share more
‘‘denatured’’ epitopes with the same human proteins expressed
in bacteria and purified as inclusion bodies. Another possible
explanation for the IHC superiority is that fixed cells exposes also
New Cell Subsets Identification
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the cytoplasm making more antigens available for the antisera,
while by flow cytometry only surface proteins are detected.
However, there were three main reasons that made the flow
cytometry more suited for our purposes: i) the easier access to
blood samples rather than lymph node biopsies; ii) the possibility
to perform multiple color staining on the cells of interest; iii) the
possibility to gate and analyze fractions of very rare cells subsets
(,1–2%) which would pass mostly undetected in a screening
performed by IHC.
Remarkably, a large majority of the newly identified proteins
are expressed on a fraction of B cells. This is somehow expected
since a lower number of B cell markers have been characterized as
compared to T cell markers. For a long period of time CD4+ T
cells have been considered the ‘‘master’’ regulators of the immune
responses [26] and a lot of functionally distinct T helper or
Figure 5. Pre-characterization of MOSC-1 expressing CD34+ cells. (A) Representative distribution of MOSC-1 on CD34+ cells. Cord blood
mononuclear cells are stained with MOSC-1-specific serum diluted 1:150. The analysis upon gating on CD34highCD45dim cells is shown. (B) CFC assay
with MOSC-1 positive cells. CD34+MOSC-1+ and CD34+MOSC-1- cells were purified by Fluorescence Activated Cell Sorting. The purity of the
populations used in the assays was .90%. The same number of cells from the two populations (100–500) were plated in methocult medium (Stem
Cell Tech.) and incubated at 37uC for 14 days. Then the frequency of white, red and mixed colonies was calculated. The average of 5 independent
experiments is shown. (C) Phenotype of CD34+ cells expressing MOSC-1. Cord Blood mononuclear cells were stained with anti MOSC-1 antiserum at
1:150 dilution point after magnetic enrichment of CD34+ cells. All the samples were stained also with anti CD34 and anti CD45 mAbs and, in turn,
with anti CD71, anti CD33, anti CD133, anti CD90, anti CD13, anti CD7 and anti CD10 mAbs. The expression of these markers is shown on the
population of CD34+MOSC-1+ cells. An analysis representative of three independent experiments is shown. (D) MOSC-1 distribution on PBMC. PBMC
from healthy donors were stained with anti MOSC-1 antiserum at 1:150 dilution points. The samples were stained also with anti CD3 (T cells), anti
CD19 (B cells), anti CD56 (NK cells) and anti CD14 (monocytes) mAbs to gate the correct subpopulation. An analysis representative of 5 different
experiments is shown. In all the staining (C,D) serum from not immunized mice was used as negative control. (E) MOSC-1 RT-PCR on PBMC. RNA from
PBMC and from the indicated magnetically purified subpopulation (Purity .99%) was retro-transcribed and amplified with MOSC-1 specific primers.
Beta actin gene was amplified as positive control.
doi:10.1371/journal.pone.0034395.g005
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regulatory subsets have been described and characterized
[27,28,29,30,31,32,33,34]. B cells were generally considered
antibody- producing effector cells and a combination of few
surface markers was used to discriminate between human naı¨ve B
cells, memory B cells (central memory) and antibody-producing
plasma cells (effector memory) [35]. However, B cells are more
heterogeneous than previously thought. Although usually over-
shadowed by the production of antibodies, the ability of B cells to
play important antibody-independent functions (antigen presenta-
tion, T cell and Dendritic cell regulation and cytokine and
chemokyne production) is well documented [36]. Through these
functions B cells can profoundly influence the formation and
organization of secondary lymphoid tissues and T cell develop-
ment, activation and function [36]. Moreover, antibody-indepen-
dent B cell functions can contribute either to the development or
to the prevention of autoimmune diseases [37]. It seems
reasonable to assume that a larger amount of functionally distinct
subsets contribute in various ways to antibody-independent
functions of B cells and that such subsets could be defined by
the expression of few proteins poorly characterized so far, that we
have identified with our polyclonal antisera library.
In the field of stem cells, the paucity of surface markers, allowing
the separation of stem cells subpopulations with a specific fate,
represents the major problem in stem cell based therapies. Thus,
the identification of such new stem cell markers would significantly
improve their use in therapy. In the present study we aimed at
identifying new hematopoietic stem cells subsets. Hematopoietic
stem cell (HSC) transplantation is, nowadays, the only widely used
stem cell-based therapy [38,39,40]. Even though HSCs have been
extensively studied in the last 30 years and a number of lineage-
specific markers have been identified, the need of new subsets
identification to better understand the hematopoiesis mechanisms
is still strong. With our screening we have identified the protein
MOSC-1 on a subset of cord blood derived CD34+CD45dim cells
as well as on monocytes, where its expression was revealed also by
gene expression profile. We have performed a phenotypic
characterization of CD34+ cells expressing MOSC-1 and we
have purified by FACS sorting the fraction of MOSC-1 positive
cells that generated almost exclusively CFU-G and CFU-M
colonies in CFC assays. Our data are not sufficient to demonstrate
that CD34+ cells expressing MOSC-1 are fully committed
monocytes progenitors. In vivo studies with both MOSC-1
positive and negative CD34+ cells would be necessary to conclude
that MOSC-1 expressing cells generate monocytes, but the
extremely low number of highly purified cells that we can get by
FACS sorting makes these experiments almost impossible. De
Bruin and colleagues describes the possibility to induce in vitro
monocytes differentiation from myeloid progenitors in the
presence of interferon-gamma [41]. Also these kind of experiments
could help to demonstrate whether MOSC-1+ CD34+ cells are
able to generate monocytes, however the complete characteriza-
tion of hematopoietic progenitors is not the point we wanted to
made in this paper. In fact, the goal of this work is to demonstrate
the usefulness of our antisera library to identify new cell subsets
and, in our opinion, our results are sufficient to suggest that
MOSC-1 is a marker defining the monocytes progenitors therefore
identifying a new functional subset of CD34+CD45dim cells.
In conclusion, we generated a library of polyclonal antisera
specific for poorly characterized human surface proteins. This
library is a powerful discovery tool. In fact, our sera allow not only
to identify new molecules expressed on different cell subsets, but
also to perform a phenotypic and functional pre-characterization
of the newly identified cell subset. Moreover, we were able to
discover the expression on cord blood CD34+ cells of new
proteins, not previously outlined by other methods, indicating that
we have developed a very sensitive approach particularly
appropriate when working with poorly represented cells.
Supporting Information
Data S1 Paper describing the generation and validation
of the antisera library used in this study.
(PDF)
Figure S1 IHC analysis with sera specific for well-
known proteins. Sections of human lymph nodes were
pretreated with an antigen retrieval solution and were then
incubated with the indicated antisera. Detection steps were done
using a commercially available kit according to the manufacturer
instructions. Peroxidase activity was developed with 3-3-diamino-
benzidine-copper sulfate to obtain a brown-black end product. A)
anti CD2, B) anti CD3 gamma, C) anti CD8 alpha, D) anti CD8
beta, E) anti CD72, F) anti CD69.
(TIFF)
Figure S2 Results of sera screening by FACS on PBLs
and cord blood cells. A) FACS analysis of sera positive on
PBLs. PBLs were stained with the indicated sera. The samples
were also stained with anti CD3, anti CD19 and anti CD56 mAbs
to analyze the sera reactivity upon gating on the different
subpopulations. B) PBMCs are treated for 24 hours with 1 mg/
ml of PHA. After the treatment both un-stimulated and stimulated
cells are stained with KRTCAP-3-specific serum. C) FACS
analysis of sera positive on cord blood cells. Cord blood
mononuclear cells are stained with the indicated sera. The
samples are stained also with anti CD45 and anti CD34 mAbs
to perform the analysis upon gating on CD34high CD45dim cells.
In all the cases the average with the relative standard deviation of
five different donors is shown for each serum.
(TIFF)
Figure S3 Assessment of antisera specificity on Hela
transfected cells by FACS analysis. Hela cells were
transfected with a myc-tag version of the proteins identified with
the sera library. At 24 hours from the transfection cells were
stained with the indicated sera as described in Methods section. As
negative control un-transfected wt Hela cells stained with the same
antisera were used. The FACS analysis for the CRISP-1 and
MOSC-1 proteins is not shown since the two proteins are secreted
and mouse antisera cannot be used in intra cellular staining
because of the high background.
(TIFF)
Figure S4 Differentiation assay on OP9 cells. Because of
the reactivity of MOSC-1-specific antiserum on B cells, we have
tested the capability of CD34+ cells expressing MOSC-1 to
generate mature B cells upon differentiation on OP9 stromal cells.
MOSC-1 positive and negative cells were sorted by FACS (purity
.98%) and analyzed for the up-regulation of the B cell marker
CD19 upon 14 days of culture on OP9 cells. 500 cells were plated
for each condition. MOSC-1 positive cells were unable to generate
B cells in this assay. This result is in agreement with the hypothesis
that MOSC-1 is expressed only by mature monocytes and binds a
receptor on B cells.
(TIFF)
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